Global Push to Eliminate Trachoma, the World’s Leading Infectious Cause of Blindness

Trachoma, the world’s leading infectious cause of blindness, remains a devastating disease affecting the poorest and most marginalised communities globally, but a new editorial in the British Medical Journal argues that complete elimination is achievable with sustained effort and strategic refocus.

The disease, caused by repeated infection with the bacterium Chlamydia trachomatis, creates a painful cycle of inflammation and scarring in the inner eyelid. Left untreated over years, the eyelashes turn inward and scratch the cornea—a condition called trachomatous trichiasis—causing chronic eye pain, functional limitation, and eventual blindness. According to the World Health Organization, approximately 1.9 million people are currently blind or visually impaired from trachoma, with a further 97.1 million people living in endemic areas at risk of the disease.

The burden falls disproportionately on women and children in Africa, Asia, Latin America, the Middle East, and rural Australia, where poverty, limited access to clean water, and poor sanitation create ideal conditions for transmission through hands, clothing, hard surfaces, and flies. Trachomatous trichiasis particularly affects women because of their greater proximity to infected children. Beyond individual suffering, the disease exerts an enormous economic toll—the WHO estimates the annual productivity loss from trachoma at between £2.3 billion and £4.2 billion, rising to approximately £6.4 billion when trichiasis is included.

A Remarkable Decline, But Work Remains

Despite these sobering figures, global progress has been extraordinary. The number of people at risk has fallen from 1.5 billion in 2002 to 97.1 million as of November 2025—a 94 per cent reduction. This milestone reflects decades of sustained effort by national health ministries, local communities, and international partners implementing the WHO-endorsed SAFE strategy: Surgery for trachomatous trichiasis, Antibiotics to clear infection through annual mass treatment programmes, Facial cleanliness promotion, and Environmental improvement to reduce transmission.

The SAFE strategy has proven effective and adaptable across diverse settings. In 2024 alone, 87,349 people received corrective surgery for advanced trachoma, whilst 44.4 million people in endemic communities received antibiotics for infection control. The WHO has validated 27 countries as having successfully eliminated trachoma as a public health problem, including Egypt, India, China, Mexico, and several African nations.

Major research initiatives have underpinned this success. The Global Trachoma Mapping Project (2012–2016) conducted the largest series of infectious disease surveys ever undertaken, collecting data from 2.6 million people across 29 countries. This work is now being advanced by Tropical Data, which has examined over 13.1 million people across more than 4,000 surveys in 55 countries—equating to an average of one person examined for trachoma every 25 seconds since 2012.

The Final Push Requires Strategy and Resources

Despite this progress, the BMJ editorial emphasises that reaching the WHO’s 2030 elimination target will require recalibrated strategies and renewed commitment. Nearly 100 million people remain at risk, and significant funding gaps persist. Experts estimate that approximately $300 million (£240 million) is needed to fill shortfalls in surgery provision, antibiotics, epidemiological surveys, and priority research.

The disease’s persistence in low-income and marginalised communities reflects broader structural challenges: inadequate water access, limited sanitation infrastructure, and healthcare systems stretched thin by competing demands. Addressing these requires not only disease-specific interventions but investment in the social determinants of health—improved water systems, sanitation facilities, and robust health education programmes.

As the editorial notes, global productivity loss from trachoma underscores the case for investment. The return on investment in trachoma elimination is substantial: every pound spent on SAFE interventions prevents far greater economic losses from blindness and visual impairment. Additionally, trachoma often coexists with other neglected tropical diseases in the same populations, meaning integrated control efforts can achieve efficiency gains.

The Role of Data and Partnership

The success of trachoma control to date has been underpinned by rigorous data collection and strong partnership between health ministries, research institutions, and international organisations. This collaborative model must be strengthened and sustained to achieve final elimination. Countries such as Egypt and Fiji have demonstrated that validation of elimination status is possible, providing proof of concept for others.

The challenge ahead is maintaining momentum in an era of competing global health priorities and finite resources. The COVID-19 pandemic disrupted trachoma programmes in several countries, highlighting the fragility of progress when health systems face multiple crises. Building resilience into elimination programmes through integrated approaches and community engagement will be critical.

Key Takeaways

• The number of people at risk from trachoma has fallen 94 per cent since 2002, from 1.5 billion to 97.1 million, representing one of global health’s major achievements.
• Despite this progress, approximately 1.9 million people remain blind or visually impaired from trachoma, predominantly in low-income countries in Africa, Asia, and Latin America.
• The SAFE strategy—surgery, antibiotics, facial cleanliness, and environmental improvement—has proven effective and adaptable, with 27 countries now validated as having eliminated trachoma.
• Approximately £240 million in additional funding is needed to close gaps in surgery, antibiotics, surveillance, and research to achieve WHO’s 2030 elimination target.
• Trachoma elimination requires not only disease-specific interventions but also investment in water, sanitation, and health infrastructure that address the root causes of transmission.

What This Means for Kent Residents

Whilst trachoma is not endemic in the United Kingdom, the disease has global resonance for British healthcare professionals and international development advocates. The NHS supports global health initiatives through training programmes and partnerships with tropical medicine centres, including the London School of Hygiene and Tropical Medicine. For Kent residents working in international development, healthcare, or charitable sectors focused on neglected tropical diseases, trachoma elimination represents a tangible example of how sustained, evidence-based global health strategies can achieve transformational change. Those concerned about supporting efforts to eliminate trachoma can engage with established organisations working on neglected tropical diseases or contribute to wider campaigns improving water, sanitation, and health infrastructure in low-income countries.